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Abstract Fibroblasts are the main matrix producing cells
of the dermis and are also strongly regulated by their matrix
environment which can be used to improve and guide skin
wound healing processes. Here, we systematically investi-
gated the molecular effects on primary dermal fibroblasts in
response to high-sulfated hyaluronan [HA] (hsHA) by
quantitative proteomics. The comparison of non- and high-
sulfated HA revealed regulation of 84 of more than 1,200
quantified proteins. Based on gene enrichment we found that
sulfation of HA alters extracellular matrix remodeling. The
collagen degrading enzymes cathepsin K, matrix metallo-
proteinases-2 and -14 were found to be down-regulated on
hsHA. Additionally protein expression of thrombospondin-1,
decorin, collagen types I and XII were reduced, whereas the
expression of trophoblast glycoprotein and collagen type VI
were slightly increased. This study demonstrates that global
proteomics provides a valuable tool for revealing proteins
involved in molecular effects of growth substrates for further
material optimization.
1 Introduction
The skin is the largest organ of the human body. It has
many essential functions like body temperature regulation,
oxygen uptake, pathogen defense and fluid loss prevention.
Thus dermal wounds can cause severe health problems by
the restriction of these functions. The therapeutic band
width of skin wound treatment includes dressing with
autografts, allografts, xenografts or tissue-engineered skin
substitutes (TESS). TESS have been proven to be a good
alternative to conventional treatment by grafting of skin
wounds [1]. Clinical products from different companies are
extensively reviewed by Eisenbud et al. [2] and Damanhuri
et al. [3], while Metcalfe and Ferguson [4] have reviewed
developments of bioengineered artificial skin. The usage of
cell-free scaffolds as matrix supports for self-regeneration
of skin is an alternative to skin biopsies and dermal cell
culturing. Especially cell-free scaffolds based on biode-
gradable substances like polylactides, collagens and/or
glycosaminoglycans (GAGs) which mimic the extracellular
matrix (ECM) are good alternatives to conventional skin
grafting [5–8].
A promising approach for the development of new
artificial ECMs (aECMs) for wound healing of skin tissue
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is the integration of chemically modified natural ECM
components. In particular sulfated GAG have been sup-
posed to improve wound healing of skin tissue by the
interaction of negatively charged sulfate groups with
cytokines, growth factors and dermal cells [9, 10].
Sulfated derivatives of GAGs mimic the behavior of
heparin, the most biological active natural GAG compound
which plays an important role in wound healing [11].
Heparin interacts with a huge variety of different proteins,
like growth factors FGFs (fibroblast growth factors)-1, -2
and -7 [12] or cytokines such as platelet factor 4 [13],
interleukin 8 (IL-8) [10, 14] or interferon gamma [15].
Heparin further binds to adhesion proteins like selectins
[16], the heparin-binding growth associated molecule [13]
and fibronectin [17]. Protein binding to heparin promotes
different functions like protection from proteolysis (i.e.
FGFs-1, -2 and -7) [12, 18] or modification of biological
activity shown for transforming growth factor b1 (TGF-b1)
[13]. Thus heparin and other sulfated GAG have an influ-
ence on key processes of wound healing like inflammation,
cell proliferation or cell–matrix interactions [13]. Most
interactions between sulfated GAG and proteins are gov-
erned by negatively charged sulfate groups which form
ionic bonds with basic amino acid residues [10, 12, 13, 15].
Hence, cell studies with sulfated GAG can provide
valuable information for the engineering of new skin sub-
stitutes. We have chosen hyaluronan (HA) to investigate
the effect of chemical sulfation. HA is the most suited
GAG for this study since naturally HA does not contain
sulfate groups. It has a regular sequence of alternating units
of N-acetylglucosamine and glucuronic acid and is not
covalently linked to proteins. Additionally, HA can be
chemically modified without loss of structure [11]. Since
our research focus is on acquiring knowledge about the
influence of synthetized aECMs for improved wound
healing of skin tissue we have chosen dermal fibroblasts
(dFbs) as model cells for investigation of our modified
aECM. They are crucial for wound healing of skin tissue
and strongly regulated by their surrounding ECM [19]. The
previous work of van der Smissen et al. [20] showed that
sulfated GAGs improved initial cell adhesion and prolif-
eration of dFbs in a sulfation dependent manner. By testing
a few selected mRNA of involved key proteins the
expression levels of collagen type I a chain, HA synthase 2
and matrix metalloproteinase-1 (MMP-1) were found to be
significantly reduced on high-sulfated GAGs, whereas low-
sulfated GAG derivatives only slightly changed the mRNA
expression of these components.
On the basis of these data [20], the influence of HA
sulfation on the expression of other proteins by a non-
targeted approach is of great interest since this will allow
detecting so far unrecognized signaling pathways in
response to the tested biomaterials. We analyzed the
influence of aECMs consisting of collagen type I mixed
with HA or its high-sulfated derivative (hsHA) on protein
level. For that reason, we have chosen stable isotope
labeling by amino acids in cell culture (SILAC) which is a
well-established method enabling accurate relative quan-
tification of thousands of proteins in an untargeted
approach [21, 22]. As long as primary cells can be culti-
vated for a sufficient time to obtain quantitative isotope
labeling, SILAC provides superior protein coverage and
better quantitative reproducibility in comparison to the
usage of cells or organs from different individuals or label
free quantification [23]. Especially relative quantification
to a control of the same donor within one measurement
reduces variability.
Global analyses provide a broader overview and higher
protein coverage than targeted experiments. Computational
analyzes of regulated proteins according to databases like
PANTHER (Protein ANalysis THrough Evolutionary
Relationships) [24] reveal protein cluster enriched
according to their molecular functions and biological pro-
cesses. Bioinformatics tools like DAVID [25] additionally
calculate enrichment factors and determine statistical sig-
nificance of these clusters.
While these approaches are limited to detecting known
pathways the global approach also offers the chance to
unravel so far unknown proteins or complexes that might
also be pivotal to the process of interest. In order to extract
this potential from the wealth of raw data gathered through
omics approaches it is necessary to build up cell type and
research specific databases. More specifically the effects of
aECM on different cell types involved in wound healing
should be summarized in a database allowing a focused
comparison with future data.
A generally important aspect of global analysis is the
assumption that the conditions do not cause an overall
extreme stress to the cells, since then the effects would
reflect all but not dominantly specifically mechanism about
the subtle changes occurring during adaptation. The gen-
eral effects can be monitored by the amount of overall
changes and as a valid assumption the significantly
(P \ 0.05) changed proteins should not exceed 5–10 %.
In this study over 2,000 proteins were unambiguously
identified and the gene enrichment process revealed that
HA sulfation affects predominantly ECM remodeling by
simultaneously down-regulation of ECM degenerating
proteins like MMPs-2 and -14 as well as cathepsin K
(catK). Additionally, other ECM proteins including de-
corin, thrombospondin-1 (TSP-1), and collagen types I, VI
and XII are regulated. Beside this detailed information on
coordinated ECM remodeling the summary of affected
pathways and molecular functions allows to build a
database for monitoring of aECM caused effects on
fibroblasts.
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2 Materials and methods
2.1 Sample preparation
The study was conducted according to Declaration of
Helsinki Principles (1975) and was approved by the local
ethics committee (065-2009).
Primary human dFbs from healthy breast skin were
isolated as previously described [26] by dispase II (Roche
Diagnostics GmbH, Mannheim, Germany) mediated
removal of epidermal sheet and digestion of the dermal
compartment with collagenase (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany). Cell suspension was passed
through 70 lM filters (BD Biosciences, Bedford, MA,
USA) to remove tissue debris. In total four biological
replicates deriving from different donors were applied in
this study.
Cells were cultured with Dulbecco’s Modified Eagle
Medium (DMEM, Biochrom AG, Berlin, Germany) sup-
plemented with 10 % fetal calf serum (FCS, Biochrom AG,
Berlin, Germany) and 1 % penicillin/streptomycin (PAA
Laboratories GmbH, Pasching, Austria) at 37 C, 5 % CO2
until confluence. For experiments cells between passages
2–8 were used [20].
An overview of the experimental workflow after isola-
tion of primary dFb is shown in Fig. 1. For isotope labeling
dFb were cultivated in SILAC DMEM (Pierce SILAC
Protein Quantitation Kit—DMEM, Pierce Biotechnology,
Rockford, USA) containing either 0.798 mmol/l heavy
13C14N lysine and 0.398 mmol/l heavy 13C15N arginine
(heavy medium) or 12C14N lysine and 12C14N arginine
(light medium) supplemented with 10 % dialyzed FCS for
10 days on polystyrene (PS) culture plates with medium
change every 2 days.
4.0 9 105 (24 h exposure) and accordingly 1.5 9 105
cells (5 days exposure) were transferred to 75 cm2 cell
culture flasks coated with different aECMs consisting of rat
tail collagen type I (C) (BD Bioscience, Heidelberg, Ger-
many) and HA (Aqua Biochem, Dessau, Germany) or hsHA
(provided by Innovent e.V., Jena, Germany) described by
van der Smissen et al. [20] and incubated for 1 or 5 days. At
the time point 5 days the monolayer appeared with a donor
dependent confluence of 70–100 %. One day incubation
was meant to determine immediate cell responses to hsHA,
Fig. 1 Experimental workflow. I Primary dermal fibroblasts are
prepared from healthy female donors. II Primary dermal fibroblasts
are precultured either in light medium (L) or heavy medium
(H) containing isotopically labeled lysine and arginine until heavy
amino acid content is larger than 95 % in the proteins. III Cells are
cultured on different aECMs. Control-matrix and test-matrix have
different isotope labeling. IV After culturing for 1 respectively
5 days, cells are harvested, lysed and mixed 1:1 according to their
protein content. Proteins are fractionated by SDS-PAGE and digested
in-gel by trypsin. V Peptides are analyzed by LC–MS/MS. VI MS
data is processed by Maxquant. Pairs of light and heavy labeled
peptides enable relative protein quantification. Regulated proteins are
determined. VII Proteins considered to be regulated are subjected to
bioinformatics tools like DAVID and PANTHER for cluster analysis
according to biological processes and molecular function (cluster
diagram was made on http://string-db.org/)
J Mater Sci: Mater Med (2012) 23:3053–3065 3055
123
whereas 5 days of incubation should reflect changes in the
proteome of almost confluent grown dFbs. The appropriate
culture variations are listed in Table 1. These variations
offer the comparison of light and heavy labeled cells after
the cultivation on the different aECMs.
Proteomic analysis was carried out on the basis of cell
lysates. Therefore, fibroblasts were harvested after days 1
or 5 post seeding by addition of 0.25 % EDTA (Sigma, St.
Louis, MO, USA) in 19 PBS (PAA) to prevent damage of
integrins by trypsin. The cell pellet was stored on ice and
washed three times with cold 19 PBS before the final
centrifugation for 6 min, 12,000 rpm at 4 C. The super-
natant was discarded and cell pellet immediately frozen at
-80 C until further use.
Harvested cells were disrupted in 100 ll lysis buffer
containing 6 M urea, 2 M thiourea and 100 mM ammo-
nium bicarbonate by vortexing for 3 min. Cell debris and
undissolved material were removed by centrifugation
(16,0009g, 10 min, 18 C). Protein concentration of the
supernatants was measured using Quick Start Bradford
Protein Assay (Biorad, Hercules, CA) with bovine serum
albumin as reference. Samples gained from the different
aECMs were combined at 1:1 (w/w) protein ratio with the
appropriate control (PS or C).
2.2 SDS-PAGE and in-gel digestion of proteins
In order to increase the amount of quantified proteins,
samples were fractionated using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). For the
gel separation, 15 lg protein of each sample were mixed
3:1 with 49 Laemmli sample buffer (12 % [w/v] SDS,
6 % [v/v] b-mercaptoethanol, 30 % [w/v] glycerol,
150 mM Tris–HCl [pH 7.0], 0.04 % [w/v] bromphenol
blue) and incubated 1 h at 37 C. Protein separation was
performed by 12 % SDS-PAGE with a 4 % stacking gel.
Gel electrophoresis was stopped after proteins entered
approximately 3 cm in the gel. The Coomassie staining
procedure was performed according to Mu¨ller et al. [27].
The protein lanes were cut in five equal gel slices. In-gel
digestion of protein was performed similar to Mo¨rbt et al. [28]
with 100 ng trypsin per slice (trypsin sequencing grade from
bovine pancreas, Roche, Mannheim, Germany). Samples
were concentrated by vacuum centrifugation and reconsti-
tuted with 0.1 % (v/v) formic acid after tryptic digestion.
2.3 Liquid chromatography tandem MS analysis
Tryptic peptides from in-gel digestion were separated by
nano-high performance liquid chromatography (nano-
HPLC) prior to mass spectrometry (MS) analysis to
increase the number of quantified peptides and corre-
sponding proteins. Liquid chromatography tandem MS
analysis was performed according to Mu¨ller et al. [27] with
some slight modifications. Peptides were analyzed with a
nano-HPLC system (nanoAquity, Waters, Milford, MA,
USA) coupled online with an LTQ Orbitrap XL mass
spectrometer (Thermo Fisher Scientific, San Jose, CA,
USA) via a nano-electrospray ion source (TriVersa Nano-
Mate, Advion, Ithaca, NY, USA). Samples were injected
on a trapping column (nanoAquity UPLC column, C18,
180 lm 9 20 mm, 5 lm, Waters) and washed with 2 %
acetonitrile containing 0.1 % formic acid and a flow rate of
15 ll/min for 8 min. A C18 UPLC column (nanoAcquity
UPLC column, C18, 75 lm 9 150 mm, 1.7 lm, Waters)
was used for peptide separation. Peptides were eluted using
a gradient from 2 to 85 % acetonitrile, 0.1 % formic acid
(0 min, 2 %; 2 min, 2 %; 7 min, 6 %; 55 min, 20 %;
73 min, 30 %; 91 min, 40 %; 94 min, 85 %) with a flow
rate of 300 nl/min and a column temperature of 40 C.
Table 1 aECMs, according
abbreviations and the applied
culture medium and incubation
time












Collagen type I/hyaluronan (C-HA) Light medium 1
5
Collagen type I/C-hsHA Heavy medium 1
5
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MS analysis was performed with a spray voltage of
1.8 kV in positive ion mode. The mass spectrometer
automatically switched between full scan MS mode (from
400 to 1,400 m/z, R = 60,000) and MS2 acquisition. Pep-
tide ions exceeding an intensity of 5,000 counts were
fragmented within the linear ion trap by collision induced
dissociation (isolation width 4 m/z, normalized collision
energy 35, activation time 30 ms, activation Q 0.25). A
dynamic precursor exclusion of 3 min for tandem MS
measurements was applied.
2.4 Data analysis
Protein identification and relative quantification was carried
out with the software MaxQuant [29] (version 1.2.0.18,
Max Planck Institute of Biochemistry, Munich, Germany).
Peptides with the same sequence but different labeling
states elute at the same retention time. Heavy to light pep-
tide pairs can be detected by their distinct mass shifts
according to the labeling with heavy arginine and lysine.
MaxQuant uses the intensity of heavy and light labeled
peptide pairs to calculate relative peptide abundances. The
derived peptide intensity ratios belonging to the same pro-
tein are the basis for relative protein quantification.
Within the MaxQuant workflow, database searching was
carried out by the Andromeda search engine [30] against a
reverse concatenated IPI human database (version 3.68)
including a contaminant list. Recalibration of precursor
masses by the option ‘‘first search’’ with a 20 ppm mass
tolerance against the human first search database provided
by MaxQuant.org. Trypsin with maximum two missed
cleavages was set as protease. Carbamidomethylation of
cysteine was specified as fixed modification, and oxidation
of methionine and acetylation of the protein N-terminal
were defined as variable modifications. A peptide mass
tolerance of 6 ppm was applied. For tandem MS identifi-
cation six top peaks per 100 Da were chosen and searched
with a fragment ion mass tolerance of 0.5 Da.
Peptide and protein false discovery rates were limited to
1 %. Protein identification required at least two unique
peptides. The minimal peptide length was set to six amino
acids. For protein quantification, the minimal peptide ratio
count was set to 2. The option ‘‘match between runs’’ was
used for samples measured within the same batch. Re-
quantification of proteins was also applied.
Proteins with a log2 fold change (FC) above 0.5 or
below -0.5 were considered to be up- respectively down-
regulated. Furthermore, only proteins showing in at least
three out of four replicates regulation in the same direction
and an average FC of all replicates fulfilling the criteria for
regulation were considered as significantly regulated.
For identification of significantly regulated clusters of
functionally related regulated proteins the web-based
bioinformatics tool DAVID [24] was used. The list of
regulated proteins was subjected to DAVID, whereas all
identified proteins served as background for cluster anal-
ysis. Protein clustering was performed according to bio-
logical and molecular function derived from the
PANTHER classification system [24].
2.5 Control experiments for significance estimation
of regulation thresholds
Experiments with primary cells often show large variation
between different donors. Additionally, technical variance
is another error source. With regard to these issues, we
tested the significance of our regulation thresholds with
two control experiments. Each control experiment was
performed in triplicates. The first experiment was to eval-
uate the labeling effect of the SILAC experiments.
Therefore, protein samples of the same donor from cells
grown on light and heavy medium with collagen type I as
matrix were mixed 1:1 (w/w) according to their protein
content. The second control experiment examined the
donor effect and included protein samples from three
donors. Therefore, heavy and light labeled protein samples
of different donors were mixed 1:1 (w/w) according to their
protein content (donor A heavy ? donor B light, donor B
heavy ? donor C light, donor A light ? donor B heavy).
Further treatment and measurement was similar to the other
samples. Proteins with a log2 FC larger than 0.5 or lower
than -0.5 were defined as regulated.
2.6 Western blot and zymography
Data analysis with MaxQuant and the bioinformatics tool
DAVID resulted in a set of regulated protein clusters.
Selected proteins belonging to regulated clusters were
chosen for further confirmation by western blotting or zy-
mography. Western blots of cell lysates were performed
with antibodies against MMP-14, TSP-1, collagen types I
and VI (a chain 1). The enzymatic activity of MMP-2 in
the culture supernatant was tested by gelatine zymography
[26] to investigate whether altered MMP-2 expression
leads to activity changes.
3.5 9 105 cells were seeded on aECM provided in petri
dishes (94 mm diameter) and incubated for 72 h with
DMEM/10 % FCS, another 24 h with DMEM/0 % FCS to
generate serum free supernatants and additional 24 h with
DMEM/10 % FCS to gain an incubation time of 5 days in
total. Samples from six different donors were applied for
validation by western blotting and zymography.
Cell extracts were prepared by detaching cells with
0.05 % trypsin/0.02 % EDTA (Biochrom, Berlin, Ger-
many) and cooled lysis of cell pellets with RIPA-buffer
(50 mM HEPES, 150 mM NaCl, 5 mM EDTA, 1 mM
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EGTA, 1 % Triton X-100, 0.1 % SDS, 1 % deoxycholate,
1 mM dithiothreitol [Roth, Karlsruhe, Germany; Serva,
Heidelberg, Germany; Sigma, Taufkirchen, Germany]).
Protein lysates were separated by SDS-PAGE with appro-
priate SDS gels (Amersham ECL gels, GE Healthcare,
Mu¨nchen, Germany) and blotted on OPTITRAN BAS83
membrane. Primary antibodies for MMP-14 (rabbit-anti-
human, clone ID: EP1264Y, Epitomics, Burlingame,
USA), TSP-1 (rabbit-anti-human, Abcam, Cambridge,
United Kingdom), collagen type VI a chain 1 (rabbit-anti-
human, Atlas Antibodies, Stockholm, Sweden), collagen
type I a 1 (rabbit-anti-human, Sigma) and GAPDH (mouse-
anti-human, Merck-Millipore, Darmstadt, Germany) were
combined with IRDye 680RD goat-anti-rabbit or IRDye
680RD goat-anti-rabbit (LI-COR, Lincoln, USA) as sec-
ondary antibodies.
Cell-free supernatants were concentrated by ultrafiltra-
tion using vivaspin six columns (GE Healthcare) for
MMP-2 gelatine zymography [26]. An amount of 5 lg of
concentrated supernatant was diluted in a sample buffer
(0.3 M Tris–HCl pH 8.8, 4 % saccharose, 10 % SDS and
0.1 % bromphenol blue), applied to a 10 % SDS-gel con-
taining, 0.1 % gelatine, and was electrophoretically sepa-
rated. After electrophoresis, gels were washed in 2.5 %
Triton X-100 for 30 min and were incubated overnight at
room temperature in a development buffer containing
0.05 M Tris–HCl, pH 8.0, 8 mM CaCl2. MMP-2 associated
gelatine digestion was visualized as white bands in the gel
after staining with 0.1 % Coomassie blue R250 and clearing
with 7.5 % acetic acid. MMP-2 activity was quantified by
densitometric measuring (Intas, Go¨ttingen, Germany). The
absolute integrated area under the peak was determined.
3 Results
3.1 Significance estimation of regulation thresholds
In order to estimate the effects of technical variance during
cell culture (labeling effect) and the biological variance
caused by different donors (donor effect), we set up two
control experiments. Samples from three different donors
were used for the significance estimation.
To investigate the labeling effect, cells from three dif-
ferent donors were split up and cultivated in either heavy
(containing 13C14N lysine and 13C15N arginine) or light
SILAC medium. Heavy and light stable isotope labeled
cells of the same donor were lysed, mixed and analyzed.
Analogously the donor effect was determined by mixing
differentially labeled samples of the different donors.
Between 600 and 900 proteins were quantified by Max-
Quant. Analysis of labeling effect resulted in average
0.6 % of all identified proteins fulfilling the up-regulation
threshold, whereas 5.9 % pass the threshold for down-
regulation. This is clearly showing that the abundance of
light labeled proteins is overestimated during protein
quantification process even so typical contaminants such as
keratins, trypsin as well as rat collagen type I, which was
used as aECM component, were defined as contaminants
and thus discarded during the quantification process.
Six proteins are found to be regulated in all three rep-
licates with a log2 FC less than -0.5. Namely, two Ras-
related proteins (RAB2, RAB5), histone H1.2, dermcidin
and collagen type I a chains 1 and 2 are fulfilling the
threshold in all samples. The fact that all of these proteins
are showing a higher abundance of light labeled protein in
this control experiment indicates that these proteins can be
classified as contaminants. Dermcidin for example is a 91
amino acid long antimicrobial peptide secreted by perspi-
ratory glands which can occur as a contaminant. Even rat
collagen type I was already inserted to the contaminant list
of MaxQuant, the abundance of light labeled human col-
lagen type I is higher than the heavy labeled counterpart in
this control experiment. Only unique peptides were
accepted for calculation of heavy to light ratios. Which
means that collagen type I contamination has to stem from
another source than the applied aECM.
The donor effect was estimated by measuring a mixture of
heavy and light control samples of different donors. On
average 12.9 % of all identified proteins show a log2 FC less
than -0.5, and 8.2 % have a FC larger than 0.5. To evaluate
whether this donor effect is random or not, only proteins which
had the same direction of FC in all replicates were used for
further analysis. Only 0.1 % of proteins identified in all rep-
licates fulfilled the threshold criteria and have the same
direction of FC. This demonstrates that variability of protein
abundance by different donors is exclusively a random effect.
To estimate the false positive rate (FPR) of regulated
proteins in our SILAC experiment, we used a stochastic
equation based on combinatorics. The FPR is calculated by
summing up, that three out of four or four out of four
measurements are representing a regulation by chance in
the same direction. As probability for false positive up- or
down-regulation we took the experimental values derived
from the donor effect measurements as it showed the
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With Eq. 1 a FPR lower than 1 % was calculated for the
chosen protein regulation thresholds demonstrating high
significance.
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3.2 Classification of quantified proteins
In the main proteomic experiments cellular response to the
different aECMs (C-HA and C-hsHA) after different incu-
bation times (1 or 5 days) was investigated. Overall 2,419
proteins were quantified. Between 61 and 70 % of these
proteins were quantified in at least three out of four bio-
logical replicates. Cell compartment classification of the
identified proteins was done according to gene ontology
(GO) annotations using the software STRAP (Software
Tool for Rapid Annotation of Proteins) [31] (Supplemen-
tary Table 1). Most proteins were assigned to the cytoplasm
(35 %) followed by the nucleus (34 %) and the plasma
membrane (15 %). Since we found only a few regulated
proteins for C-HA (1.9 %) but a more prominent effect for
C-hsHA (3.6 %), we calculated the ratio between C-hsHA
and C-HA at corresponding time points (Table 2). Thus we
eliminated the effect of the control matrix by dividing the
ratios of C-hsHA and C-HA. This is supported by the nor-
mal distribution around zero in the density plot of log2 FCs
for C-hsHA related to C-HA at day 5 post seeding (Fig. 2a).
The fraction of regulated protein was between 2 (C-hsHA/
C-HA day 1) and 6.7 % (C-hsHA/C-HA 5 days) (Table 2).
Proteins fulfilling the regulation thresholds were clustered
using the web-based tool DAVID [25] according to their
molecular functions respectively their biological process
using the PANTHER GO database [24]. The cluster analysis
revealed one significant cluster (enrichment score [1.5) for
the comparison of C-hsHA and C-HA at day 5 post seeding.
Ten regulated proteins were associated to the ECM and cell
adhesion (MF00178, MF00179, BP00124). Based on the low
number of regulated proteins on day 1 post seeding, no sig-
nificant clusters could be determined. Classification and
clustering of regulated proteins according to the PANTHER
database is shown in Fig. 2.
3.3 Effects of HA sulfation on the expression of ECM
and cell adhesion related proteins
Bioinformatics analysis with DAVID shows regulation of
10 proteins associated with ECM (PANTHER cluster:
MF00178, MF00179, BP00124) at day 5 (Fig. 2) according
to HA sulfation. We manually added catK to the ECM
cluster since it is an important protein for collagen degra-
dation [32].
The regulated proteins MMP-14, collagen types I, VI
and TSP-1 were chosen to confirm the SILAC results
by western blotting (Fig. 3; Supplementary Table 2).
MMPs-2, -14, collagen type VI and TSP-1 showed the
same regulation as revealed by SILAC analysis. On the
other hand, collagen type I western blots could not verify
down-regulation of collagen type I on C-hsHA after 5 days
of exposure.
Additionally, MMP-2 zymography was performed to
measure the relative activity in the culture supernatants.
Both, protein expression determined by SILAC and
MMP-2 activity in the culture supernatant are diminished
by HA sulfation.
4 Discussion
Previous investigations indicated that matrices with sul-
fated GAGs modulate cellular responses like cell adhesion,
cell proliferation or matrix production [20]. In this study,
we set up a SILAC experiment to extend knowledge about
protein regulation caused by sulfation of HA with an un-
targeted approach. We focused on fibroblasts since these
cells are crucial for wound closure and synthesis of new
tissue.
We used primary dFb from healthy individuals in our
experiments to examine effects on the proteome as close as
possible to the in vivo situation. This is indispensable if the
results should be referred to the original cell metabolism.
For example Pan et al. [33] showed that a hepatoma cell
line had up-regulated cell-cycle associated functions and
down-regulation of drug metabolism compared to their
cognate primary cells. Contrary to our results, Abatangelo
et al. [34] reported that soluble hsHA (substitution degree
3) had no growth promoting effect on a mouse fibroblast
cell line (NTC L929). This result might also be caused by
the usage of an immortalized cell line. However, a clear













Total protein quantifications 2262 2150 2244 2224 2109 1885












Down-regulated 0 13 7 36 24 38
Up-regulated 7 12 1 18 9 46
Regulated proteins (%) 0.44 1.90 0.51 3.53 2.28 6.92
a Values for C-hsHA/C-HA are calculated by measured ratios of C-HA and C-hsHA at corresponding time points
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drawback of experiments with primary cells lies in their
higher biological variance compared to cell lines.
SILAC is a well-established method to relatively
quantify the abundance of proteins in a shotgun approach.
It is well suited for experiments with primary cells because
control and treated sample from the same donor are
compared within one measurement. Therefore, the effect of
the donor is minimized. Nevertheless, experiments with
primary cells cause high variance of results. In order to
cope with this, we applied an extended set of controls for
the labeling as well as the donor effect. The results are
showing that for primary dFb, SILAC can be used to
investigate changes in the proteome with a FPR lower than
1 % with the applied criteria.
As expected the applied aECMs showed good biocom-
patibility which is in line with toxicity studies for sulfated
HA [34]. Our previous results already showed that sulfa-
tion of HA increases cell adhesion and proliferation [20].
The good biocompatibility is reflected by the fact that there
were no significantly regulated clusters detectable after
Fig. 3 Validation of selected proteins regulated by HA sulfation at
day 5 post seeding by western blotting and zymography. a Compar-
ison of log2 FC values derived by SILAC, western blotting and
zymography. *T test P value \0.05. b Representative western blots.
c Representative MMP-2 zymography of culture supernatant
Fig. 2 Cluster analysis of proteins regulated by HA sulfation at day 5
post seeding. a The log2 FC between the matrices C-hsHA and C-HA
is plotted against the density. FCs show a normal distribution around
zero. b Clustering of proteins regulated by HA sulfation according to
PANTHER biological processes. c Clustering of proteins regulated by
HA sulfation according to PANTHER molecular functions. d FCs of
proteins clustered by DAVID according to PANTHER biological
processes and molecular function (MF00178 ECM, MF00179 ECM
structural protein, BP00124 Cell adhesion). *T test P value \0.05.
#catK was added manually to the cluster according to its collagen
degrading function in the lysosomes
b
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24 h of culture. In order to allow future work to focus on
the really relevant pathways and molecular functions in
terms of effects of aECM, we summarized the results of
gene enrichment analyses in Fig. 4. The figure shows rel-
evant protein clusters with information about significant
enrichment of regulated proteins. The diagram highlights
that neither apoptosis nor stress response are regulated by
HA sulfation. Thus any cell activation or danger programs
are excluded for the application of C-hsHA. However,
proteins in those relevant clusters could be selected and
used for fast and reliable detection with targeted approa-
ches like selected reaction monitoring [35], western blot-
ting or enzyme linked immunosorbent assay [36].
We focused on the significant clusters to show relevant
effects caused by HA sulfation. The gene enrichment
analyzes resulted in a clear enrichment in terms of cell
adhesion and regulation of the ECM. The biochemical
relationship between members of this cluster are shown in
Fig. 5a.
Collagen type I, which is the main type in the dermal
ECM [37], is the first member of the regulated protein
cluster (Fig. 2). Collagen type I gives tensile strength to
skin and bone tissue [38]. It replaces destroyed dermal
tissue and is deposited mainly by myofibroblasts upon
stimulation by TGF-b [39]. Western blotting could not
confirm decreased collagen type I expression in this study.
Nevertheless, the previous study of van der Smissen et al.
[20] support the results derived by SILAC.
Collagen type XII protein expression is also reduced in
response to hsHA. It is localized at the surface of collagen
fibrils and acts as a bridge between them [40]. Increased
expression of collagen type XII by dFbs is known to pro-
mote collagen type I gel contraction [41]. Thereby defor-
mability is decreased and migration of dFb into the ECM is
inhibited [40]. dFbs produce more collagen type XII when
they grow on attached compared to floating collagen type I
gels [42], but the underlying mechanism is not discovered
by now.
On the other hand, cells on C-hsHA express higher
levels of collagen type VI. This ECM compound is known
to be produced by dFb when they get confluent to generate
an appropriate cell environment [43].
TSP-1 is also down-regulated for C-hsHA. The expres-
sion of TSP-1 is increased in response to tissue damage,
inflammation, or growth factors like platelet derived
growth factor, TGF-b and basic FGF [44, 45]. Freshly
synthetized TSP-1 gets integrated in the ECM or binds to
the cell surface, where it is quickly internalized and
degraded [46]. TSP-1 has the ability to activate TGF-b and
to inhibit angiogenesis [45, 47, 48]. It is also known to
influence adhesion, migration, cytoskeletal organization
and apoptosis of cells by interaction with different cell
receptors [45]. Thereby the mode of TSP-1 action strongly
depends on the cell type and its cell surface receptors. For
example smooth muscle cell migration is induced [45],
while essential signal cascades like the extracellular signal-
Fig. 4 Comparison of regulated
and non-regulated relevant
protein clusters by HA sulfation
according to PANTHER
a biological processes and
b molecular function at day 5
post seeding. The bars indicate
the number of identified
proteins which were regulated
(gray) or not regulated (black)
for each protein cluster. The two
graphs are divided in three
boxes. Regulated protein
clusters are in the upper boxes
(red). Protein clusters with less
than five proteins are in the
middle boxes (yellow). Protein
clusters which are not regulated
and include more than five
protein identifications are in the
lower boxes (green) (Color
figure online)
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regulated kinase (ERK) pathway are inhibited by TSP-1
[49]. The ERK pathway includes a phosphorylation cas-
cade of different proteins in response to growth factors,
cytokines or hormones. It controls different cell functions
like cell proliferation, differentiation and apoptosis [50].
Aberrant activation of the ERK pathway is present in many
cancers [51].
In our study, TSP-1 abundance was lower for the
C-hsHA matrix which had pro-proliferative properties on
dFb in a previous study [20]. Hence, TSP-1 can promote
proliferation when TGF-b is bound whereas unbound
TSP-1 reduces proliferation by inhibition of the ERK
pathway (Fig. 5a). C-hsHA strongly binds TGF-b [52] and
thereby prevents TGF-b-signaling in fibroblasts grown on
C-hsHA (Anderegg U, personal communication). There-
fore, TSP-1 might be less effective on C-hsHA in addition
to its decreased expression observed here.
Additionally, decorin was found to be down-regulated
for C-hsHA. This proteoglycan with attached chondroitin
and dermatan sulfate chains interacts with many proteins of
the regulated ECM cluster. Two different binding sites
related to collagen fibrils enable decorin to bridge collagen
types I and VI [53] (Fig. 5a). Decorin has also the ability to
bind to collagen type XII [54]. It is essential for ECM
cross-linking since decorin deficient mice produce abnor-
mally fused collagen bundles which lead to increased skin
fragility [55]. On the other hand, cell attachment to TSP-1
is inhibited by decorin through binding to its cell adhesive
site [56] (Fig. 5a). Decorin is also important for binding
different growth factors like FGF-2 with its sulfated GAG
chains [57].
The MMPs-2 and -14 (also named MT1-MMP) and their
inhibitor tissue inhibitor of metalloproteinases 2 (TIMP-2)
build a complex regulation network for collagen degrada-
tion during wound healing. Besides collagen type I,
membrane bound MMP-14 has a huge variety of different
substrates including laminin, lumican, integrin aV, trans-
glutaminase, CD44H, syndecan 1 and IL-8 [58]. Collagen
fibers are degraded by MMP-14 in short fragments which
are further degraded intracellular by phagocytosis involv-
ing catK [32, 59].
MMP-2 is secreted in its inactive form proMMP-2 and
gets activated by MMP-14 (Fig. 5b) [60, 61]. Lee et al.
[59] showed that MMP-14 but not MMP-2 is necessary for
phagocytosis of collagen type I. Indeed, MMP-2 is able to
cleave interstitial but not helical collagen type I [62]. Thus
MMP-14 is the key enzyme for collagen phagocytosis.
TIMP-2 is an inhibitor of both MMPs-2 and -14. Interest-
ingly, activation of proMMP-2 by MMP-14 is enhanced by
a low amount of TIMP-2, whereas higher concentrations
lead to inhibition of MMP-14 [63] (Fig. 5b). Additionally,
blocking of TIMP-2 by an antibody abrogates MMP-2
activation [63, 64]. Moreover, HA has also the ability to
induce proMMP-2 activation [65]. Sulfated HA might not
have the ability to induce proMMP-2 activation, which
results in lower abundance of active MMP-2 for cells
grown on C-hsHA.
CatK is also related to ECM degradation processes due
to its ability to degrade collagens, elastins and proteogly-
cans [66]. Collagens are degraded after endocytosis in the
lysosomes where catK is highly expressed [32]. CatK is
usually not expressed in healthy skin, while its expression
Fig. 5 Biological processes and the relationship between proteins in
the regulated ECM associated cluster. a Scheme of protein relation-
ships in a biochemical context. The connection lines between the
different proteins indicate activation, inhibition, binding, or degrada-
tion of associated proteins or pathways. Proteins, which were found to
be down-regulated on C-hsHA are green, whereas up-regulated
proteins are marked bold red. b Influence of TIMP-2 on activation of
MMP-2 according to the proposed mechanism by Nagase et al. [61].
High concentrations of TIMP-2 inhibit proMMP-2 conversion by
blocking the active site of MMP-14. On the other hand, low
concentrations of TIMP-2 are required for MMP-2 activation. TIMP-2
binds to MMP-14 with its N-terminal domain. In a second step
proMMP-2 is recruited by MMP-14 bound TIMP-2. Closely located
free MMP-14 binds proMMP-2 and cleaves the propeptide to activate
MMP-2 (Color figure online)
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is induced by inflammation or in scar formation [32, 66].
For example it is up-regulated in synovial fibroblasts,
which are key players in rheumatic arthritis because of
their cartilage degrading activity [66]. In our experiment
MMPs-2, -14, TIMP-2 and catK are down-regulated when
comparing the aECMs C-hsHA and C-HA. Furthermore
previous results showed, that MMP-1 is significantly down-
regulated on mRNA level for C-hsHA [20] suggesting
altogether that matrix remodeling is diminished by hsHA.
This hypothesis is strengthened by the down-regulation of
collagen types I and XII expression. Cells growing on non-
sulfated matrix might degrade the provided aECM and
build up their own matrix according to their requirements.
Interestingly, therapeutic wound dressings which result
in an reduced ECM degradation or direct inactivation of
MMPs are known to improve healing of chronic skin
wounds since disorders in the MMP–TIMP balance can
lead to fibrosis, metastasis or tumor growth [37]. There are
several clinical products on the market, which target MMPs
to rebalance the wound environment and to improve
healing of chronic wounds. Promogran for example
consists of oxidized regenerated cellulose and collagen
which binds and inactivates MMPs [67]. The product Fi-
bracol also reduces the activity of MMPs by competitive
inhibition with collagen [68]. A formulation of metal ions
and citric acid is used in DerMax wound dressings to
reduce oxygen free radicals and MMP-2 activity [69, 70].
In conclusion, introduction of sulfate groups in HA of
growth substrates influences the expression of MMPs and
other ECM related proteins which are involved in ECM
remodeling by dFbs. These effects occur without induction
of stress, promising good biocompatibility of hsHA.
Especially, considering the described positive effects on
healing of chronic wounds by inhibition of MMPs along
with increased proliferation [20] and the low cellular stress
level further encourages the application of hsHA as an
appropriate therapeutic agent in wound dressings.
Our study shows that quantitative proteomics is a
valuable tool for unbiased evaluation of aECM effects. It
can be used to preselect suited aECM prior to animal
testing. Moreover, the untargeted protein analysis provides
a set of biological markers and pathways for further
detailed investigations. Thereby animal experiments can be
reduced to promising aECMs for clinical application.
Nevertheless, in vitro experiments cannot completely
simulate the situation in vivo. Ultimately further investi-
gations of aECMs in animal experiments are indispensable
to proof their influence on wound healing and long term
effects.
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